THC Global Group Limited (ASX: THC) has received the final licences required for Australian production and distribution of narcotic medicines, which includes medical cannabis independent for both the ‘Bundy’ Facility and the Southport Manufacturing facility.
- Queensland Department of Health has granted Schedule 4 and Schedule 8 licences;
- This will enable the company to manufacture and wholesale S8 and S4 drugs including medical cannabis;
- Production validation will be completed by the end of the December and supply to Australian patients will start in early 2020.
At AEST 12:56 PM, the stock was trading at $0.395 per share, up by 3.947% from its previous close.
There is no investor left unperturbed with the ongoing trade conflicts between US-China and the devastating bushfire in Australia.
Are you wondering if the year 2020 might not have taken the right start? Dividend stocks could be the answer to that question.
As interest rates in Australia are already at record low levels, find out which dividend stocks are viewed as the most attractive investment opportunity in the current scenario in our report.